PASG Passage BIO Inc
Price (delayed)
$0.391
Market cap
$24.3M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.07
Enterprise value
$12.2M
Passage Bio, has the mission to provide life-transforming gene therapies for patients with rare, monogenic CNS diseases that replace their suffering with boundless possibility, all while building lasting relationships with
Highlights
The EPS has grown by 42% YoY and by 9% from the previous quarter
The net income is up by 37% year-on-year and by 6% since the previous quarter
The equity has contracted by 45% YoY and by 16% from the previous quarter
The quick ratio has decreased by 43% YoY and by 21% QoQ
Key stats
What are the main financial stats of PASG
Market
Valuations
Earnings
Shares outstanding
62.15M
Market cap
$24.3M
Enterprise value
$12.2M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.39
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$64.77M
Net income
-$64.77M
EBIT
-$64.77M
EBITDA
-$61.69M
Free cash flow
-$47.99M
Per share
Balance sheet
Liquidity
EPS
-$1.07
EPS diluted
-$1.07
Free cash flow per share
-$0.79
Book value per share
$0.99
Revenue per share
$0
TBVPS
$1.7
Total assets
$102.41M
Total liabilities
$41.15M
Debt
$25.48M
Equity
$61.26M
Working capital
$59.45M
Debt to equity
0.42
Current ratio
4.07
Quick ratio
3.96
Net debt/EBITDA
0.2
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-54%
Return on equity
-78.6%
Return on invested capital
-66.2%
Return on capital employed
-78%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PASG stock price
How has the Passage BIO stock price performed over time
Intraday
1.3%
1 week
-15.02%
1 month
-24.52%
1 year
-69.92%
YTD
-31.05%
QTD
10.73%
Financial performance
How have Passage BIO's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$64.77M
Net income
-$64.77M
Gross margin
N/A
Net margin
N/A
The operating income is up by 37% year-on-year and by 6% since the previous quarter
The net income is up by 37% year-on-year and by 6% since the previous quarter
Growth
What is Passage BIO's growth rate over time
Valuation
What is Passage BIO stock price valuation
P/E
N/A
P/B
0.39
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 42% YoY and by 9% from the previous quarter
The stock's price to book (P/B) is 65% less than its 5-year quarterly average of 1.1 and 35% less than its last 4 quarters average of 0.6
The equity has contracted by 45% YoY and by 16% from the previous quarter
Efficiency
How efficient is Passage BIO business performance
The ROIC has contracted by 10% from the previous quarter and by 3.9% YoY
The company's return on equity fell by 8% QoQ and by 8% YoY
PASG's return on assets is up by 3.9% year-on-year but it is down by 3.6% since the previous quarter
Dividends
What is PASG's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PASG.
Financial health
How did Passage BIO financials performed over time
Passage BIO's total assets is 149% more than its total liabilities
Passage BIO's current ratio has decreased by 44% YoY and by 21% from the previous quarter
The quick ratio has decreased by 43% YoY and by 21% QoQ
The debt is 58% less than the equity
The debt to equity has soared by 75% YoY and by 17% from the previous quarter
The equity has contracted by 45% YoY and by 16% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.